CoChat

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

Open access
Angioni, Davide, Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J.R., Braunstein, J.B., Sabbagh, M., Bittner, T., Pontecorvo, M., Bozeat, S., Dage, J.L., Largent, E., Mattke, S., Correa, O., Gutierrez Robledo, L.M., Baldivieso, V., Willis, D.R., Atri, A., Bateman, R.J., Ousset, P.-J., Vellas, B., Weiner, M. · 2022 · The Journal of Prevention of Alzheimer's Disease
Cited by 126

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Timely and accurate diagnosis of Alzheimer's disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14283/jpad.2022.85

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 126

Metadata

Authors
Angioni, D., Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J. R., Braunstein, J. B., Sabbagh, M., Bittner, T., Pontecorvo, M., Bozeat, S., Dage, J. L., Largent, E., Mattke, S., Correa, O., Gutierrez Robledo, L. M., Baldivieso, V., Willis, D. R., Atri, A., Bateman, R. J., Ousset, P.-J., Vellas, B., & Weiner, M.
Venue
The Journal of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Published
2022-10
Volume
9
Issue
4
Pages
569-579
ISSN
2274-5807 (ISSN-L)
OpenAlex
W4307342071
Cited by
126
References
24
FWCI
14.40
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force. https://app.cochat.ai/papers/10.14283/jpad.2022.85
The paper
Angioni, D., Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J. R., Braunstein, J. B., Sabbagh, M., Bittner, T., Pontecorvo, M., Bozeat, S., Dage, J. L., Largent, E., Mattke, S., Correa, O., Gutierrez Robledo, L. M., Baldivieso, V., Willis, D. R., . . . Weiner, M. (2022). Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2022.85

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.